



A WNS COMPANY

# Implantable Loop Recorder (ILR)

---

## *Cardiology Services*

P\_9845, P\_9852

Guideline Initiated: 06/30/2019

Copyright © 2022

Last Review Date: 04/19/2022





A WNS COMPANY

## Table of Contents

Implantable Loop Recorder (ILR) .....	3
Guideline .....	3
Contraindications to an Implantable Loop Recorder (ILR) .....	4
Implantable Loop Recorder (ILR) Removal .....	5
References .....	5
Procedure Codes .....	8
Definitions/Key Terms .....	9
Disclaimer & Legal Notice .....	11

## Implantable Loop Recorder (ILR)

**NCD 20.15**

See also, **NCD 20.15**: Electrocardiographic Services at <https://www.cms.gov/medicare-coverage-database/search.aspx> if applicable to individual's healthplan membership.

### Guideline

An implantable loop recorder may be medically appropriate when there is **NO** other concurrent cardiac monitoring and the medical record demonstrates **ANY** of the following:

- Atrial fibrillation (AFib) when **ALL** of the following: [13]
  - **ANY** of the following:
    - Ablation postprocedure monitoring for dysrhythmia. [20]
    - Anticoagulation discontinuation (to ensure absence of A-fib prior to stopping) or when transition to oral anticoagulant therapy. [5] [33]
  - Arrhythmia was **NOT** detected on inpatient telemetry and long-term external ambulatory cardiac monitoring, and further evaluation is warranted for treatment planning. [10]
- Palpitations evaluation when arrhythmia is suspected and **ALL** of the following: [2] [4] [17] [21] [27] [30] [41] [6]
  - Symptoms are infrequent (30 days between symptoms) and recurrent (less often than in 48 hour intervals). [24]
  - Evaluation included: history, physical exam, ECG, tilt-table test and orthostatic blood pressure measurements, and was non-diagnostic or indeterminate .
  - Long-term external ambulatory cardiac event monitoring was nondiagnostic.
- Stroke, cryptogenic or transient ischemic attack (TIA) that was recent (within 90 days) with suspected paroxysmal atrial fibrillation and **ALL** of the following: [10] [12] [13] [14] [22] [35] [44] [23]
  - Anticoagulation candidacy (anticoagulants are not contraindicated or refused).

- Arrhythmia was **NOT** detected on inpatient telemetry and long-term external ambulatory cardiac monitoring, and further evaluation is warranted for formal diagnosis and treatment
- Atrial fibrillation (subclinical) is suspected.
- CHA2DS2-Vasc score is 2 or higher.
- Initial evaluation including CT or MRI Brain, electrocardiogram (ECG), echocardiography and neurological workup were indeterminate for the etiology of the stroke or stroke symptoms. [6] [27]
- Syncope that is unexplained, when **ANY** of the following:
  - Arrhythmic etiology is suspected and **ALL** of the following: [3] [4] [9] [19]
    - Syncope is of uncertain origin, infrequent (30 days between symptoms) and recurrent (in less than 48 hour intervals). [24] [25] [27] [28] [37]
    - Evaluation included: history, physical exam, ECG, tilt-table test and orthostatic blood pressure measurements **AND** it was nondiagnostic or indeterminate for syncope etiology or did **NOT** lead to specific treatment indications for primary prevention ICD or a pacemaker. [27]
    - Cardiac arrhythmia was **NOT** detected on trial of external ambulatory cardiac event monitoring for at least 30 days.
  - High-risk syncope and external ambulatory cardiac event monitoring (for a minimum of 30 days) was nondiagnostic.<sup>1</sup>[6] [32]

## Contraindications to an Implantable Loop Recorder (ILR)

An implantable loop recorder (ILR) may be contraindicated for **ANY** of the following situations: [31]

- Bleeding disorder
- Clinical status makes procedure inappropriate (eg, active infection)
- Remote monitoring inaccessible

---

<sup>1</sup>High-risk syncope may be considered when syncope: occurs during exertion or while in supine position; there are palpitations at time of syncope; there is a family history of sudden (cardiac) death; signs of Brugada, signs of arrhythmogenic right ventricular dysplasia; and diagnoses that include: non-sustained ventricular tachycardia, bundle branch block with QRS duration of more than 120 msec, Wolff-Parkinson-White syndrome, prolonged or short QT interval, severe structural heart disease with signs of impaired left ventricular ejection fraction, and hypertrophic cardiomyopathy. [32]

## Implantable Loop Recorder (ILR) Removal

Removal of an implantable loop recorder (ILR) may be medically appropriate when the medical record supports the need for ILR removal (eg, device failure, infection, monitoring completed for treatment planning).

## References

- [1] "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation." January, C.T, Wann, S.L, et. al. Circulation, 130(23); pp: e199-e267, December 2014.
- [2] "2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy." Elliott, P.M.; Anastakis, A.; et. al. European Heart Journal, 35; pp: 2733–2779, 2014
- [3] "2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society." Shen, Win-Kuang, Shelton, Robert S., et. al. Name of Journal, 14(8); pp: e218-e254, August 2017
- [4] "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society." Al-Khatib, S., Stevenson, W.G., et. al. Circulation, 138(13); pp: e272-e392. August 1, 2018
- [5] "2017 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS)/Asia Pacific Heart Rhythm Society (APHRS)/Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE) expert consensus statement on catheter and surgical ablation of atrial fibrillation."Calkins, H., Hindrick, G., Cappato, R., et al.Heart Rhythm, 14(10); pp: e275-e444,October 2017
- [6] "2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry." Steinberg, J.S., Varma, N., et. al. Heart Rhythm, 14(7); pp: e55-e96, July 2017.
- [7] "2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society." Kusumoto, F.M., Schoenfeld, M.H., et. al. Heart Rhythm, 16(9); pp: e128-e226, September 2019
- [8] "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Stout, K.K., Daniels, C.J., et. al. Journal of the American College of Cardiology, 73(12); pp: e81-e192, April 2019.

- [9] "2018 European Society of Cardiology (ESC) Guidelines for the diagnosis and management of syncope." Brignole, M., Moya, A., et. al. European Heart Journal, 39; pp: 1183-1948, 2018.
- [10] "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons." January, C.T., Wann, L.S., et al. Circulation, 140(2); pp: e125-e151, July 2019.
- [11] "2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." Ommen, S.R., Mettal, S., et. al. The Journal of Thoracic and Cardiovascular Surgery, 162(1), 2021, Elsevier
- [12] "The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation." Andrade, J.G., Aguilar, M., et. al. Canadian Journal of Cardiology, 36(12); pp: 1847-1948, December 2020
- [13] "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)." Hindricks, G., Potpara, T, et. al. European Heart Journal, Name of Journal, 42(5); pp: 373-498, February 2021
- [14] "2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society." Varma, N., Cygankiewicz. I.; et. al. Circulation: Arrhythmia and Electrophysiology, 14(12), February 2021
- [15] "ACC/AHA Guidelines for Ambulatory Electrocardiography. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines." Bernstein, S.J., Deedwania, P.C., et. al. Journal of the American College of Cardiology, 34(3); 1999
- [16] "AHA/ACCF Scientific Statement on the Evaluation of Syncope." Strickberger, S.A., Benson, D.W., et. al. Circulation, 113(2); pp: 316-327, 2016
- [17] "Ambulatory ECG monitoring in the age of smartphones." Sanders, D., Unger, L., et. al. Cleveland Clinic Journal of Medicine, 86(7); pp: 483-493, July 2019
- [18] "Ambulatory Electrocardiography: Holter and Event Monitoring " David Flinders and Scott Akin. Pfenninger and Fowler's Procedures for Primary Care, 4th Edition, 2020, Chapter 73; pp: 457-473, Elsevier
- [19] "Approach to the Patient with Cardiac Arrhythmias ." Curtis, A.B., Tomaselli, G.F. Braunwald's Heart Disease, Edition 12. 2022. Chapter 61; pp: 1145- 1162. e7, Elsevier
- [20] "Catheter Ablation: Clinical Aspects." Biase, L.D., Aagaard, P, et. al. Cardiac Electrophysiology: From Cell to Bedside, Seventh Edition 2018, Chapter 124, 1194-1210, Elsevier

- [21] "Clinical Approach to Patients with Palpitations." F. Giada and A. Raviele Cardiac Electrophysiology Clinics, 10(2); pp: 387-392, 2018, Elsevier
- [22] "Cryptogenic Stroke and Underlying Atrial Fibrillation." Sanna, T., Diener, HC, et. al. New England Journal of Medicine, 370: 2478-2486, 2014
- [23] "Current and Future Use of Insertable Cardiac Monitors." Giancaterino, S; Luperio, F; et al. JACC: Clinical Electrophysiology, 4(11); pp: 1383-96, 2018
- [24] "Current Guidelines and Clinical Practice." Love, Charles J. Cardiac Electrophysiology Clinics, 13(3); pp: 459-471, September 2021
- [25] "Diagnosis of cardiac arrhythmias." Miller, J; Tomaselli, G; Zipes, D. Braunwald's, 11th Edition, 2019. Chapter 35; pp: 648-669. Elsevier
- [26] "Diagnostic value of implantable loop recorders in patients with unexplained syncope or palpitations." Radovanovic, N.N., Pavlovic, S.U., et. al. Annals of Noninvasive Electrocardiology, 26(5); e12864, September 2021
- [27] "European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population." Nielsen, J.C., Lin, YJ, et. al. Name of Journal, 24(3); pp: 123-45 June 2020
- [28] "Evaluation of Syncope in Older Adults." Hogan, T.M., Constantine, S.T., Crain, A.D. Emergency Medicine Clinics of North America, 34(3); pp: 601-627, August 2016
- [29] "How to Differentiate Syncope from Seizure." R. Sheldon Cardiology Clinics, 33(3); pp: 377-385, August 2015
- [30] "Implantable loop recorder in clinical practice." Bisignani, A.; De Bonis, S.; et. al. Journal of Arrhythmia, 35(1); pp: 25-32, November 2018
- [31] *Implantable Loop Recorder*. Vilcant V, Kousa O, Hai O. [Online]. Available: <https://www.ncbi.nlm.nih.gov/books/NBK470398/><https://www.ncbi.nlm.nih.gov/books/NBK470398/>. Accessed January 2022. National Center for Biotechnology Information (NCBI).
- [32] "Implantable loop recorders." Breitenstein, Alexander Cardiovascular Medicine, 21(03); pp: 55-68, March 2018
- [33] "Implantable Loop Recorders - Syncope, Cryptogenic Stroke, Atrial Fibrillation." Mittal, Suneet Cardiac Electrophysiology Clinics 13(3); pp: 439-447, July 2021
- [34] "Indications, Complications, and Diagnostic Yield of Implantable Loop Recorder Monitoring." Ibrahim, O., Drew, D., Baranchuk, A. Canadian Journal of Cardiology, 32(10), pp: S287-S287, October 2016
- [35] "Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population." Ziegler, P.D., Rogers, J.D., et. al. International Journal of Cardiology, 244; pp: 175-179, June 2017



- [36] "Loop recorders for syncope evaluation: what is the evidence?." Cheung, C.C., Krahn, A.D. Expert Review of Medical Devices, 13(11); pp: 1021-1027, 2016
- [37] *National Coverage Determination (NCD) 20.15 Electrocardiographic Services*. Publication #: 100-3. Manual Section #:20.15. Version #: 2. [Online] Available: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=179&ncdver=2&bc=0>; Medicare Coverage Database. Accessed September 2021.
- [38] "Neurogenic Syncope Masquerading as Refractory Seizures." Belur, A.D., Madhwani, V., Ikram, S. Journal of the American College of Cardiology, 75(11) Supplement 1, March 2020
- [39] "PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: Executive Summary." Khairy, K., Van Hare, G.F., et. al. Heart Rhythm, 11(10); pp: e81-e101, October 2014
- [40] "Palpitation: Extended Electrocardiogram Monitoring: Which Tests to Use and When." Quan, K.J. Medical Clinics of North America, 103(5); pp: 785-791, September 2019
- [41] "Palpitations ." R. Katzman and J. Bailey Conn's Current Therapy 2021, pp: 45-48, Elsevier
- [42] "The Spectrum of Ambulatory Electrocardiographic Monitoring." Mond, Harry G. Heart, Lung and Circulation, 26(11); pp: 1160-1174, 2017
- [43] "Syncope, Epilepsy and Ictal Asystole: A Case Series and Narrative Review." Sowden, N., Booth, C. Heart, Lung and Circulation, 31(1); pp: 25-31, August 2021
- [44] *Understanding Diagnosis and Treatment of Cryptogenic Stroke. An Updated Health Care Professional Guide..* [Online]. Available: <https://www.stroke.org/-/media/stroke-files/cryptogenic-professional-resource-files/cryptogenic-professional-guide-ucm-477051.pdf?la=en>. Accessed December 2021. American Stroke Association A division of the American Heart Association.
- [45] "Wearable Devices for Ambulatory Cardiac Monitoring." Sana, F., Isselbacher, E.M., et. al. Journal of the American College of Cardiology, 75(13); pp: 1582-1592, April 2020

## Procedure Codes

**Table 1. Implantable Loop Recorder (ILR) Associated Procedure Codes**

CODE	DESCRIPTION
33285	Insertion, subcutaneous cardiac rhythm monitor, including programming
33286	Removal, subcutaneous cardiac rhythm monitor
C1764	Event recorder, cardiac (implantable)
E0616	Implantable cardiac event recorder with memory, activator, and programmer



## Definitions/Key Terms

**Arrhythmia** is an irregular or abnormal heart rhythm. Arrhythmia refers to any change from the normal sequence of electrical impulses of the heart, causing abnormal heart rhythms. The electrical impulses may happen too fast, too slowly or erratically – causing the heart to beat too fast, too slowly or erratically.

**Arrhythmogenic right ventricular dysplasia (ARVD)** (also called arrhythmogenic right ventricular cardiomyopathy, right ventricular cardiomyopathy or right ventricular dysplasia) is a rare type of cardiomyopathy that occurs when the muscle tissue in the right ventricle dies and is replaced with scar tissue. This disrupts the heart's electrical signals and causes arrhythmias. Symptoms include palpitations and fainting after physical activity. ARVD usually affects teens or young adults and can cause sudden cardiac arrest (SCA) in young athletes. Researchers believe that arrhythmogenic right ventricular dysplasia is an inherited disease.

2

**Atrial fibrillation (AF)** is a cardiac rhythm disorder characterized by uncontrolled atrial activation without effective atrial contraction. On the electrocardiogram (ECG), P waves are absent, and AF is characterized by rapid oscillations or fibrillatory waves that vary in amplitude, shape and timing associated with an irregular ventricular response.

- **Paroxysmal AF** terminates spontaneously or with intervention within 7 days of onset. Episodes typically convert back to sinus rhythm within 48 hours.
- **Persistent AF** is continuous AF sustained beyond 7 days.

**Brugada syndrome** is a rare inherited cardiovascular disorder characterized by disturbances affecting the electrical system of the heart. The main symptom is irregular heartbeat and, without treatment, may result in sudden death.

**Bundle branch block** is a type of conduction disorder involving partial or complete interruption of the flow of electrical impulses through the right or left bundle branches. Normally, electrical impulses travel down the right and left branches of the ventricles at the same speed, allowing both ventricles to contract simultaneously. When there is a "block " in one of the branches, electrical signals have to take a different path through the ventricle and one ventricle contracts a fraction of a second slower than the other, causing an arrhythmia.

3,4

**Cardiac event monitor** is a device used to record heart rate and rhythm for long-term monitoring of symptoms that occur less than daily. The time frame for use can be up to 30 days.

---

<sup>2</sup>American Heart Association (AHA), "Health Topics." [Online]. Available: [www.heart.org](http://www.heart.org)

<sup>3</sup>Merck & Co., Inc., "Bundle Branch Block." [Online]. Available: [www.merckmanuals.com](http://www.merckmanuals.com)

<sup>4</sup>American Heart Association (AHA), "Health Topics." [Online]. Available: [www.heart.org](http://www.heart.org)

**Catheter ablation** is a procedure performed in a cardiac catheterization laboratory during an electrophysiology study (EPS) for the purpose of destroying myocardial tissue by delivery of radio-frequency energy, electrical or cryo-energy. The procedure is used to correct heart arrhythmias.

**CHADS<sub>2</sub> Score** is an acronym for **C**ongestive heart failure, **H**ypertension, **A**ge 75 and older, **D**iabetes, and **S**troke [double weight], a score developed to more accurately predict the risk of stroke in individuals with nonrheumatic atrial fibrillation.

**CHA<sub>2</sub>DS<sub>2</sub>-VASc Score** is the expansion of CHADS<sub>2</sub> (**C**ongestive heart failure, **H**ypertension, **A**ge ≥75, **D**iabetes, **S**troke) to include three additional independent risk factors: **V**ascular disease, age between 65-74, and female sex. This score provides a better discriminated stroke risk in nonvalvular atrial fibrillation (AF) subjects with a baseline CHADS<sub>2</sub> score of 0 to 1.

**Cryptogenic stroke** is a brain infarction not clearly attributable to a definite cardioembolism, large artery atherosclerosis, or small artery disease despite extensive investigation.

**Embolic stroke of undetermined source (ESUS)** is the classification of cerebral vascular accident used to describe a non-lacunar ischemic stroke, suspected to be embolic but with no identifiable etiology (cryptogenic).

**Implantable loop recorder (ILR)** is a subcutaneous, single-lead electrocardiographic (ECG) monitoring device used for future treatment planning.

**Ischemic stroke** occurs when blood flow through an artery that supplies oxygen-rich blood to the brain becomes blocked, causing the sudden death of localized brain cells. The blockage is often the result of a blood clot and less often due to an embolus.

**Syncope** is a transient loss of consciousness and postural tone (ability to maintain or change position intentionally) due to insufficient cerebral perfusion. The loss of consciousness is associated with prompt recovery, not needing resuscitation.

**Transient ischemic attack (TIA)** is a brief interruption of the blood supply to the brain that causes a temporary impairment of vision, speech or movement. Usually, the episode lasts for just a few moments but may be a warning sign of a full scale stroke.

**Wolff-Parkinson-White (WPW)** is a congenital condition involving abnormal electrical conduction via an accessory pathway between the atria and the ventricles, which causes ventricular pre-excitation. The electrocardiogram (ECG) shows a short PR interval and a widened QRS with an initial delta wave, that reflects the accelerated ventricular contraction. WPW results in a predisposition to atrioventricular reentry tachycardia, atrial fibrillation and atrial flutter.



A WNS COMPANY

## Disclaimer & Legal Notice

### Purpose

The purpose of the HealthHelp's clinical guidelines is to assist healthcare professionals in selecting the medical service that may be appropriate and supported by evidence to safely improve outcomes. Medical information is constantly evolving, and HealthHelp reserves the right to review and update these clinical guidelines periodically. HealthHelp reserves the right to include in these guidelines the clinical indications as appropriate for the organization's program objectives. Therefore the guidelines are not a list of all the clinical indications for a stated procedure, and associated Procedure Code Tables may not represent all codes available for that state procedure or that are managed by a specific client-organization.

### Clinician Review

These clinical guidelines neither preempt clinical judgment of trained professionals nor advise anyone on how to practice medicine. Healthcare professionals using these clinical guidelines are responsible for all clinical decisions based on their assessment. All Clinical Reviewers are instructed to apply clinical indications based on individual patient assessment and documentation, within the scope of their clinical license.

### Payment

The use of these clinical guidelines does not provide authorization, certification, explanation of benefits, or guarantee of payment; nor do the guidelines substitute for, or constitute, medical advice. Federal and State law, as well as member benefit contract language (including definitions and specific contract provisions/exclusions) take precedence over clinical guidelines and must be considered first when determining eligibility for coverage. All final determinations on coverage and payment are the responsibility of the health plan. Nothing contained within this document can be interpreted to mean otherwise.

### Registered Trademarks (®) and Copyright (©)

All trademarks, product names, logos, and brand names are the property of their respective owners and are used for purposes of information and/or illustration only. Current Procedural Terminology (CPT)®™ is a registered trademark of the American Medical Association (AMA). No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form



A **WNS** COMPANY

or by any means, electronic, mechanical, photocopying, or otherwise, without permission from HealthHelp